{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"For those patients already on growth hormone replacement therapy, growth hormone will be administered as per standard of care, with standard dose ranges adjusted based upon IGF-1 monitoring. Those patients not currently receiving growth hormone replacement therapy will not be placed on therapy as a part of this study. Patients on and off growth hormone replacement therapy will be randomized in a block design to the two treatment arms to assure equal numbers in each treatment arm. The bisphosphonate to be utilized will be provided to the Arm II patients at no charge. All Arm II patients will receive the same bisphosphonate regimen, Risedronate 35 mg per oral once weekly for 18 months. All patients on arms I and II will also receive Vitamin D (400 IU p.o. daily) and calcium carbonate (500 mg p.o. twice daily) free of charge for eighteen months.","groups":[{"description":"bisphosphonate use and growth hormone use","id":"OG000","title":"Bisphosphonate and Growth Hormone Use"},{"description":"Growth hormone use only, no bisphosphonate used","id":"OG001","title":"Growth Hormone Only"}],"populationDescription":"Data analyis halted, due to low enrollment,no outcomes to report","reportingStatus":"POSTED","timeFrame":"18 months","title":"Change in Total Body Bone Mineral Density During an 18 Month Period","type":"PRIMARY"}